Assessment of bone related bio-markers in patients with rheumatoid arthritis treated with Certolizumab pegol
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000029594
- Lead Sponsor
- Graduate School of Medicine, Osaka University Department of Respiratory Medicine and Clinical Immunology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical standardized assessments and measurement of bio-markers as below; Semaphorines 3A/3E/4A/4D/7A, Osteocarcin, Bone alkaline phosphatase (BAP), type I collagen cross-linked N-telopeptide(NTX), type I collagen cross-linked C-telopeptide(CTX),tartrate-resistant acid phosphatase(TRACP)-5b, rheumatoid factor(RF), anti-CCP antibody(ACPA), Interleukin(IL)-6, TNF arufa, IL-17
- Secondary Outcome Measures
Name Time Method one (Observational study)